Sarepta Risk and the FDA
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.
SRPT $1.6B John Hempton's Newsletter
XNAS
Sarepta Therapeutics, Inc.
SRPT
1 article
$1.6B Market cap · 2026-07-31
